Suggested remit - To appraise the clinical and cost effectiveness of brentuximab vedotin within its marketing authorisation for untreated CD30-positive peropheral T-cell lymphoma
 
Status Proposed
Process STA 2018
ID number 1586

Provisional Schedule

Expected publication 12 August 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Evidence Review Group / Assessment Group Kleijnen Systematic Reviews Ltd

Consultees

Companies sponsors Takeda (brentuximab vedotin)
Others Department of Health and Social Care
  NHS England
  NHS North Lincolnshire CCG
  NHS South Norfolk CCG
  Welsh Government
Patient carer groups African Caribbean Leukaemia Trust
  Anthony Nolan
  Black Health Agency
  Bloodwise
  Cancer Black Care
  Cancer Equality
  Cancer 52
  DKMS
  Genetic Alliance UK
  Helen Rollason Cancer Charity
  Independent Cancer Patients Voice
  Leukaemia Cancer Society
  Leukaemia CARE
  Lymphoma Action
  Macmillan Cancer Support
  Maggie’s Centres
  Marie Curie
  Muslim Council of Britain
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Teenage Cancer Trust
  Tenovus Cancer Care
Professional groups Association of Cancer Physicians
  British Blood Transfusion Society
  British Committee for Standards in Haematology
  British Geriatrics Society
  British Institute of Radiology
  British Psychosocial Oncology Society
  British Society for Haematology
  British Transplantation Society
  Cancer Research UK
  NHS Blood and Transplant
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association
  UK Health Forum
  UK Oncology Nursing Society

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Accord Healthcare Ltd (hydroxydaunorubicin/doxorubicin hydrochloride)
  Advanz Pharma (prednisone/prednisolone)
  Baxter (cyclophosphamide monohydrate)
  Hospira UK Ltd (vincristine)
  Janssen-Cilag Ltd (hydroxydaunorubicin/doxorubicin hydrochloride)
  medac UK (hydroxydaunorubicin/doxorubicin hydrochloride)
  Pfizer Ltd (hydroxydaunorubicin/doxorubicin hydrochloride, vincristine)
  Sandoz Ltd (cyclophosphamide monohydrate)
  Seacross Pharmaceuticals Ltd (hydroxydaunorubicin/doxorubicin hydrochloride)
  Teva UK Ltd (hydroxydaunorubicin/doxorubicin hydrochloride, vincristine)
General commentators Allied Health Professionals Federation
  All Wales Therapeutics and Toxicology Centre
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Haematological Malignancies Group
  Leuka
  Leukaemia Busters
  Lymphoma Research Trust
  Genomics England
  Institute of Cancer Research
  MRC Clinical Trials Unit
  National Cancer Research Institute
  National Cancer Research Network
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
19 September 2019 Invitation to participate
24 June 2019 - 23 July 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance